Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

NewLimit

Biotech & Life Sciences · South San Francisco, United States · Founded 2021 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Headcount
<100
Current team size
Unlock exact value
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Epigenetic reprogramming medicines to treat age-related disease

Investors

23 investors on NewLimit's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage
Dimension
Fred Ehrsam
Elad Gil
Kleiner Perkins
Eric Schmidt
Garry Tan
Founders Fund
Series B+ 16 investors entered at this stage
Valor Equity Partners
Joshua Kushner
Nat Friedman
John Collison
Abstract Ventures
Section 32
Daniel Gross
Joe Lonsdale
Dimension
Khosla Ventures
Boost VC
Duke Management Company
Brian Armstrong
Human Capital
Eli Lilly
Patrick Collison

Global footprint

Where NewLimit has talent and traffic

Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown
Web traffic by country
21K monthly visits
across markets
🇿🇦 South Africa58.6%
🇺🇸 United States37.1%
🇫🇷 France4.3%
🇮🇳 India0.5%
Top 4 markets shown

Sentiment on X

What X is saying about NewLimit

An AI-synthesized read of the highest-engagement posts about NewLimit on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NewLimit on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles